|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1399 NEW YORK AVENUE NW |
Address2 | SUITE 300 |
| City | WASHINGTON |
State | DC |
Zip Code | 20005 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 15920-12
|
||||||||
|
6. House ID# 314640000
|
||||||||
| TYPE OF REPORT | 8. Year | 2012 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Shannon Steward |
Date | 7/20/2012 12:29:27 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Implementation of H.R. 1: Medicare Prescription Drug and Modernization Act of 2003; Issues relating to PDUFA, stimulus, issues relating comparative effectiveness and CMS coverage of FDA approved therapies. Legislation on public health preparedness and response related to pandemic influenza. Avastin-use in breast cancer treatment; general patent reform issues; implementation of the Affordable Care Act of 2010; Implementation of healthcare reform law. FDA Drug Approval and appeal oversight process. Issues related to patient and physician choice in medical treatments. Monitor PDUFA reauthorization.; Monitor implementation of Medicare pharmaceutical coverage and reimbursement and 340B provisions if the Affordable Care Act; Advocacy related ensuring access to necessary medicines
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Evan |
Morris |
|
VP Government Affairs |
|
Eli |
Kogan |
|
Assoc. Director |
|
Katherine |
Martin |
|
Director |
|
David |
Burt |
|
Director |
|
Darin |
Gardner |
|
Director |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
FY13 Labor, HHS and Education Approporation related to preparedness for pandemic influenza, HIV/AIDS programs, heptatis screening, care and treatment, and access to breast cancer treatment; Following issues related to the budget and apropriations process FY13 appropriations for FDA as well as the potential outcomes fore negotiations on altering sequestration targets via legislation; Issues related to FDA and HHS program funding, FY13 Labor Health and Human Services, and Education, and Related agencies Appropriations bill; Budget/Appropriations (House and Senate Contact Only): Monitor FY13 appropriations process: FDA funding issues and drug approval/review oversight process. Monitor the potential outcomes for negotiations on altering sequestration targets via legislation. Monitor plans for issues related to comprehensive tax reform, tax treatment of foreign-owned U.S. corporations, and tax extenders (R & D tax credit).
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Darin |
Gardner |
|
Director |
|
Katherine |
Martin |
|
Director |
|
David |
Burt |
|
Director |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Implementation of H.R. 1: Medicare Prescription Drug and Modernization Act of 2003; Issues relating to PDUFA,stimulus. Issues relating to comparative effectiveness and CMS coverage of FDA approved therapties. Issues related to the PPS ruel involving stroke guidelines. Implementation of the follow-on biologice provisions in P.L. 111-148- "Patient Protection and Affordable Care Act"; legislation on public health preparedness and response related to pandemic influenza. Influenz Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis; FDA Approval and enforcement issues. Issues relating to S.3187, FDA Safety and Innovation Act. Issues relating to antibiotic development incentives in HR 2182 and S 1734, "Generating Antibiotic Incentives Now Act of 2011"; Prescription Drug User Fee Act (PDUFA) Reauthorization;Issues related to the implementationof the Affordable Care Act of 2010;
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Eli |
Kogan |
|
Director |
|
David |
Burt |
|
Director |
|
Darin |
Gardner |
|
Director |
|
Katherine |
Martin |
|
Director |
|
Evan |
Morris |
|
VP Government Affairs |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
R&D Tax Credit (H.R. 942), FDA Appropriations, PDUFA Reauthorization; general tax issues and tax extenders (R&D tax credit) and tax treatment of foreign-owned U.S. corporations; Worked to garner support for H.R. 942, the AmericanResearch and Competitiveness Act of 2011; Monitoring proposals on US tax treatment of foreign-owned U.S. corporations;
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Eli |
Kogan |
|
Assoc. Director |
|
David |
Burt |
|
Director |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Cyber Security H.R. 942 American Research and Competitiveness Act of 2011, S.23: America Invents Act, H.R. 1249: Leahy-Smith America Invents Act; Patent Reform Act; H.R. 243 Patent Lawsuit Reform Act of 2011; H.R. 1249 Leahy-Smith America Invents Act S.23 - America Invents Act;
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Darin |
Gardner |
|
Director |
|
David |
Burt |
|
Director |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address | |
||||||
| City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
| City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |